Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
v. lappuse
... effective dates are usu- ally not the same and care must be exercised by the user in determining the actual effective date . In instances where the effective date is beyond the cut- off date for the Code a note has been inserted to ...
... effective dates are usu- ally not the same and care must be exercised by the user in determining the actual effective date . In instances where the effective date is beyond the cut- off date for the Code a note has been inserted to ...
3. lappuse
... effective date for compliance for regula- tions affecting the labeling of food products . At 51 FR 34085 , Sept. 25 , 1986 , FDA established January 1 , 1989 , as a new uniform effective date for compliance . The new uniform effective ...
... effective date for compliance for regula- tions affecting the labeling of food products . At 51 FR 34085 , Sept. 25 , 1986 , FDA established January 1 , 1989 , as a new uniform effective date for compliance . The new uniform effective ...
7. lappuse
... effective for a significant patient population requiring such con- current therapy as defined in the label- ing for the drug . Special cases of this general rule are where a component is added : ( 1 ) To enhance the safety or effec ...
... effective for a significant patient population requiring such con- current therapy as defined in the label- ing for the drug . Special cases of this general rule are where a component is added : ( 1 ) To enhance the safety or effec ...
10. lappuse
... effective be applied to all iden- tical , related , and similar drug prod- ucts to which they are reasonably ap- plicable . Any product not in compli- ance with an applicable drug efficacy notice is in violation of section 505 ( new ...
... effective be applied to all iden- tical , related , and similar drug prod- ucts to which they are reasonably ap- plicable . Any product not in compli- ance with an applicable drug efficacy notice is in violation of section 505 ( new ...
11. lappuse
... effective . ( 3 ) Any person may request an opin- ion on the applicability of such a no- tice to a specific product by writing to the Food and Drug Administration at the address shown in paragraph ( e ) of this section . ( c ) ...
... effective . ( 3 ) Any person may request an opin- ion on the applicability of such a no- tice to a specific product by writing to the Food and Drug Administration at the address shown in paragraph ( e ) of this section . ( c ) ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning